The efficacy of gefitinib supplementation for breast cancer:
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
The efficacy of gefitinib supplementation for breast cancer remains controversial. A systematic review and meta-analysis to explore the influence of gefitinib supplementation vs placebo on the efficacy of breast cancer was conducted.

Randomized controlled trials assessing the effect of gefitinib supplementation vs placebo on overall response for breast cancer patients was conducted. This meta-analysis was performed using the random-effect model.

Seven randomized controlled trials involving 927 patients were included in the meta-analysis. Overall, compared with control group for breast cancer, gefitinib supplementation revealed no obvious impact on complete response (risk ratio[RR] = 1.19; 95% confidence interval [CI] = 0.58 to 2.44), progressive disease (RR = 0.81; 95% CI = 0.59-1.11), partial response (RR = 0.67; 95% CI = 0.36-1.25), stable disease (RR = 1.02; 95% CI = 0.65–1.60), nausea or vomiting (RR = 0.99; 95% CI = 0.73–1.33), but was associated with increased incidence of diarrhea (RR = 2.80; 95% CI = 2.23–3.52), decreased incidence of hot flash (RR = 0.53; 95% CI = 0.37–0.78), and improved incidence of adverse events (RR = 1.12; 95% CI = 1.05–1.19).

Gefitinib supplementation may provide no positive effect on complete response, progressive disease, partial response or stable disease for breast cancer patients, but with the increase in adverse events.

Source: https://journals.lww.com/md-journal/Fulltext/2020/10230/The_efficacy_of_gefitinib_supplementation_for.25.aspx
Like
Comment
Share